This inventor holds 7 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Ganymed Pharmaceuticals Ag, Johannes Gutenberg-Universität Mainz, Astellas Pharma Gmbh. Active years: 2015-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:


Years Active: 2015-2023
Title: Christoph Uherek: Innovator in Cancer Treatment
Introduction
Christoph Uherek is a prominent inventor based in Ginsheim, Germany, known for his significant contributions to the field of cancer therapeutics. With a total of seven patents to his name, Uherek has focused on developing innovative solutions for treating various types of cancer.
Latest Patents
Uherek's latest patents include groundbreaking work on monoclonal antibodies against Claudin-18. These antibodies are designed to be therapeutics for treating and preventing diseases associated with cells expressing CLD18. This includes tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder. His research aims to provide effective treatment options for patients suffering from these aggressive forms of cancer.
Career Highlights
Throughout his career, Christoph Uherek has worked with notable organizations, including Ganymed Pharmaceuticals AG and Johannes Gutenberg-Universität Mainz. His work in these institutions has allowed him to advance his research and contribute to the development of innovative cancer treatments.
Collaborations
Uherek has collaborated with esteemed colleagues in the field, including Ugur Sahin and Dirk Usener. These partnerships have played a crucial role in enhancing the impact of his research and expanding the reach of his inventions.
Conclusion
Christoph Uherek's dedication to cancer research and his innovative patents position him as a key figure in the fight against cancer. His work continues to inspire advancements in therapeutic options for patients worldwide.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile